Basel, Switzerland – September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System that helps restore healthy brain functions.
Synendos successfully completed its Phase 1 clinical program in healthy volunteers, following the pre-clinical development of its lead compound SYT-510, and regulatory approval received from the EMA and MHRA.
Read more here.
”SYT-510 is the first Selective Endocannabinoid Reuptake Inhibitors (SERIs) candidate that has advanced into humans and not only demonstrated an excellent safety and tolerability profile, but also promising pharmacokinetic properties and penetration into the central nervous system.
Dr. Andrea ChiccaCo-Founder and CEO of Synendos Therapeutics
About Synendos
Synendos is a clinical-stage, neuroscience company developing breakthrough therapies for neuropsychiatric and other central nervous system (CNS) disorders such as anxiety disorders, PTSD and other indications. We utilize the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Reuptake Inhibitors (SERIs). SERIs represent first-in-class, new chemical entities that modulate the ECS through a self-limiting mode of action (MoA) with the potential to deliver meaningful benefits to patients. This novel MoA has the potential to combine treatment of a range of symptoms with sustained efficacy in large patient populations together with the potential to address a key unmet need, that of chronic tolerability, allowing more patients to stay on treatment and regain an improved quality of life. synendos.com
